PMID- 20560767
OWN - NLM
STAT- MEDLINE
DCOM- 20100720
LR  - 20211020
IS  - 1537-6613 (Electronic)
IS  - 0022-1899 (Print)
IS  - 0022-1899 (Linking)
VI  - 202
IP  - 3
DP  - 2010 Aug 15
TI  - Increases in levels of schistosome-specific immunoglobulin E and CD23(+) B cells 
      in a cohort of Kenyan children undergoing repeated treatment and reinfection with 
      Schistosoma mansoni.
PG  - 399-405
LID - 10.1086/653828 [doi]
AB  - BACKGROUND: Age prevalence curves for areas in which schistosomiasis is endemic 
      suggest that humans develop partial immunity to reinfection beginning in early 
      adolescence. We conducted a 2-year longitudinal study to determine whether 
      children infected with Schistosoma mansoni develop protection-related immune 
      responses after treatment with praziquantel and whether the development of these 
      immune responses is accelerated by frequent treatment after reinfection. METHODS: 
      Children (8-10 years old) were tested for S. mansoni every 4 months and treated 
      with praziquantel when positive (arm A; n=68) or were tested and treated at the 
      end of the 2-year follow-up period (arm B; n=49). RESULTS: Children in arm A who 
      remained free of infection during follow-up had significantly higher baseline 
      levels of schistosome-specific immunoglobulin E (IgE) than did children with > or 
      =2 repeat diagnoses of S. mansoni infection. Children with > or =2 repeat 
      diagnoses of S. mansoni infection had significantly increased levels of 
      anti-schistosome IgE and CD23(+) B cells after receiving > or =3 praziquantel 
      treatments over the course of follow-up. No increase in either parameter was seen 
      in children who received only the baseline praziquantel treatment. CONCLUSIONS: B 
      cell activation and anti-schistosome IgE are associated with resistance to S. 
      mansoni in children, and these immunological parameters can be increased by 
      multiple rounds of infections and praziquantel-induced cures.
FAU - Black, Carla L
AU  - Black CL
AD  - Center for Tropical and Emerging Global Diseases and Department of Microbiology, 
      University of Georgia, Athens, Georgia 30602-3799, USA.
FAU - Muok, Erick M O
AU  - Muok EM
FAU - Mwinzi, Pauline N M
AU  - Mwinzi PN
FAU - Carter, Jennifer M
AU  - Carter JM
FAU - Karanja, Diana M S
AU  - Karanja DM
FAU - Secor, W Evan
AU  - Secor WE
FAU - Colley, Daniel G
AU  - Colley DG
LA  - eng
GR  - R01 AI053695-01/AI/NIAID NIH HHS/United States
GR  - T32 AI060546/AI/NIAID NIH HHS/United States
GR  - D43 TW007123/TW/FIC NIH HHS/United States
GR  - T32 AI060546-02/AI/NIAID NIH HHS/United States
GR  - R01 AI053695/AI/NIAID NIH HHS/United States
GR  - D43 TW007123-02/TW/FIC NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Research Support, U.S. Gov't, P.H.S.
PL  - United States
TA  - J Infect Dis
JT  - The Journal of infectious diseases
JID - 0413675
RN  - 0 (Anthelmintics)
RN  - 0 (Antibodies, Helminth)
RN  - 0 (Receptors, IgE)
RN  - 37341-29-0 (Immunoglobulin E)
RN  - 6490C9U457 (Praziquantel)
SB  - IM
MH  - Animals
MH  - Anthelmintics/therapeutic use
MH  - Antibodies, Helminth/*blood
MH  - B-Lymphocytes/chemistry/*immunology
MH  - Child
MH  - Female
MH  - Humans
MH  - Immunoglobulin E/*blood
MH  - Kenya
MH  - Longitudinal Studies
MH  - Male
MH  - Praziquantel/therapeutic use
MH  - Receptors, IgE/*analysis
MH  - Recurrence
MH  - Schistosoma mansoni/*immunology
MH  - Schistosomiasis mansoni/drug therapy/*immunology
PMC - PMC2897938
MID - NIHMS201630
COIS- Conflicts of interest: None reported
EDAT- 2010/06/22 06:00
MHDA- 2010/07/21 06:00
PMCR- 2011/08/15
CRDT- 2010/06/22 06:00
PHST- 2010/06/22 06:00 [entrez]
PHST- 2010/06/22 06:00 [pubmed]
PHST- 2010/07/21 06:00 [medline]
PHST- 2011/08/15 00:00 [pmc-release]
AID - 10.1086/653828 [doi]
PST - ppublish
SO  - J Infect Dis. 2010 Aug 15;202(3):399-405. doi: 10.1086/653828.